O'Reilly Automotive has received an upgrade from Raymond James following a recent pullback in its stock price. This upgrade is significant as it reflects analysts' confidence in the company's long-term growth potential, especially in a competitive automotive market. Investors may see this as a positive signal, suggesting that now could be a good time to consider investing in O'Reilly, given the potential for recovery and growth.

Raymond James has raised its price target for Guardant Health's stock from $61 to $115, signaling strong confidence in the company's future performance.

Raymond James has raised the stock price target for Global Payments to $105, reflecting confidence in the company's growth and performance. This adjustment indicates a positive outlook for investors.

Raymond James has maintained a Market Perform rating on Palantir's stock, even after the company reported strong results for the third quarter. This decision reflects a cautious approach, suggesting that while Palantir's performance is commendable, there may be underlying concerns or market conditions that warrant a more reserved outlook. Investors should consider this perspective as they evaluate their positions in the stock.

Liquidia's stock price target has been raised from $41 to $47 by Raymond James, indicating strong confidence in the company's future performance. This adjustment reflects the analysts' positive outlook on Liquidia's growth potential and could attract more investors, boosting the stock's value.

Lattice Semiconductor has received a price target increase to $80 from Raymond James, reflecting strong confidence in the company's growth potential. This adjustment is significant as it highlights the positive outlook for Lattice's future performance, which could attract more investors and boost market interest.

Cigna's price target has been lowered to $350 by Raymond James due to changes in its pharmacy benefit management (PBM) contracts. This adjustment reflects concerns about the company's future profitability and market position, which could impact investors' confidence and the stock's performance. Understanding these shifts is crucial for stakeholders as they navigate the evolving landscape of healthcare management.

Raymond James has reaffirmed its 'Strong Buy' rating for Shake Shack's stock, especially following the launch of their new Big Shack burger. This endorsement is significant as it highlights investor confidence in the brand's growth potential and innovative menu offerings, which could attract more customers and boost sales.